Navigation Links
Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Date:10/21/2009

mpany's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactio
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
9. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
10. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/25/2014)... IN (PRWEB) July 25, 2014 At ... (FAA) has granted a 60-day extension for the public ... the Special Rule for Model Aircraft established by Congress ... of 2012. The 60-day extension establishes the new deadline ... United States Department of Transportation/FAA notice published in the ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... industry reveal powerful effects of, recombinant lactoferrin (tradename: ... leading to ... Oct. 10 A recently published study,in the scientific ... lactoferrin (tradename: Lacromin, see, http://www.Lacromin.com ) is a strong ...
... Oct. 10 Boston Scientific,Corporation (NYSE: BSX ... the,U.S. Food and Drug Administration (FDA) to market ... Company,plans to launch the TAXUS Liberte stent early ... the introduction of its TAXUS(R),Expresss2(TM) Atom(TM) Paclitaxel-Eluting Coronary ...
... CA, Oct. 10, 2008 Senomyx, Inc.,(Nasdaq: ... proprietary technologies,to discover and develop novel flavor ingredients ... today that Senomyx Scientific Founder,University of California, San ... Y. Tsien, Ph.D., has been awarded the Nobel,Prize ...
Cached Biology Technology:New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY 2
(Date:7/25/2014)... central nervous system disease that is caused by ... the embryonic phase. Many patients have varying degrees ... retardation. Such problems decrease the patients, functional independence ... Physical Medicine and Rehabilitation Education and Research Hospital, ... SB, using the Pediatric Evaluation of Disability Inventory ...
(Date:7/25/2014)... an unknown interaction between microorganisms and salt. When ... of salt water and is left to dry, bacteria ... 3D morphologically complex formations, where they hibernate. Afterwards, simply ... was made by chance with a home microscope, but ... journal and may help to find signs of life ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... yet of the heart of the translocon, a channel ... cell membrane. The process of transporting proteins across or ... every cell. , Howard Hughes Medical Institute investigator Joachim ... their detailed study of the translocon's core, called the ...
... sense light governs everything from seed germination, photosynthesis and ... for the first time, scientists have obtained a detailed ... a protein found in many species across life's plant, ... of the protein known as phytochrome, scientists can now ...
... , Chinese men are selectively switching from traditional ... dysfunction, but sticking with tradition for ailments such ... research published in Environmental Conservation. , The finding ... researchers at the advent of Viagra's commercial release ...
Cached Biology News:Zooming in on the protein-conducting channel 2Zooming in on the protein-conducting channel 3Scientists map one of biology's critical light-sensing structures 2Scientists map one of biology's critical light-sensing structures 3Viagra's hidden help for wildlife 2
... but comes with a shutter (controlled via a ... The DH-2000 Deuterium Tungsten Halogen ... and tungsten halogen light sources in a single ... powerful, stable output from 215-200 nm. In addition, ...
... The MSD Security ... integrated GC/MS software application ... processing, quantification, library searching ... the aspects of data ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Biology Products: